Sunday 18 October 2026
Export RLMD’s income statement to Excel — free account
Relmada Therapeutics, Inc.
RLMD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.3% and free cash flow fell 50.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.10
0.10
−3.13%
Follow RLMD
| Jun '18 | Dec '18 | Jun '19 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.46 | 0.46 | 3.83 | 80.22 | 9.37 | 14.83 | 12.26 | 8.00 | 4.45 | 14.62 |
Net Debt/EBITDA |
(0.07) | 0.32 | 0.76 | 7.71 | 1.92 | 1.69 | 0.92 | 0.93 | 0.54 | 1.57 |
Debt/Assets |
87.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.48) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.67 | 0.67 | 0.61 | 0.81 | 0.47 | 0.73 | 0.66 | 0.52 | 0.65 | 0.80 |
Capex/Depreciation |
(0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Interest Coverage |
(5.17) | — | (16.73) | — | (43.48) | (104.83) | (60.63) | — | — | — |
| 442.21% | 162.54% | (1,649.19%) | (24.34%) | (53.74%) | (80.14%) | (90.07%) | (87.51%) | (132.33%) | (94.05%) | |
| (304.53%) | (293.98%) | (261.05%) | (23.56%) | (50.53%) | (73.64%) | (83.48%) | (78.89%) | (111.57%) | (82.08%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
284.06% | 284.06% | (234.50%) | (12.99%) | (56.37%) | (60.39%) | (111.85%) | (115.80%) | (225.27%) | (65.54%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(1.92) | (1.91) | (1.66) | (1.31) | (1.78) | (5.23) | (3.50) | (1.72) | (1.72) | (1.16) |
Cash per Share |
0.71 | 0.71 | 1.46 | 12.60 | 7.51 | 12.07 | 5.01 | 3.20 | 1.49 | 2.36 |
Shareholders Equity per Share |
(1.76) | (1.76) | 1.21 | 12.52 | 6.77 | 11.87 | 4.74 | 2.84 | 1.18 | 2.19 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(1.76) | (1.76) | 1.21 | 12.52 | 6.77 | 11.87 | 4.74 | 2.84 | 1.18 | 2.19 |
Free Cash Flow |
(6.01) | (6.00) | (10.50) | (12.09) | (27.81) | (91.87) | (103.80) | (51.66) | (51.76) | (45.79) |
Working Capital |
(3.17) | (3.17) | 7.38 | 115.48 | 105.47 | 208.24 | 140.40 | 85.31 | 35.50 | 87.55 |
Capital Expenditures |
(0.01) | (0.01) | — | — | — | — | — | — | — | — |
Net Current Asset Value |
(5.82) | (5.82) | 7.38 | 115.48 | 105.47 | 208.24 | 140.40 | 85.31 | 35.50 | 86.49 |
| Other line items | ||||||||||
Quick Ratio |
0.39 | 0.39 | 3.63 | 79.93 | 9.30 | 14.08 | 11.94 | 7.90 | 4.36 | 14.46 |
Depreciation/Fixed assets |
85.27 | 0.21 | 92.50 | 0.88 | 2.92 | 0.00 | — | — | — | — |
Cash ROIC |
973.69% | 183.32% | (62.38%) | (5.21%) | (12.49%) | (21.87%) | (35.95%) | (28.43%) | (64.35%) | (25.51%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.91) | (1.91) | (1.66) | (1.31) | (1.78) | (5.23) | (3.50) | (1.72) | (1.72) | (1.16) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.18 | 0.07 | 0.16 | 0.16 | 0.08 | 0.08 | 0.30 | — | — | — |
Average Payables |
0.65 | 0.77 | 0.84 | 0.72 | 4.43 | 9.77 | 8.23 | 4.38 | 3.82 | 2.85 |
Average Assets |
2.94 | 3.05 | 6.63 | 63.68 | 117.66 | 170.76 | 188.12 | 125.23 | 71.68 | 69.91 |
Average Common Equity |
(2.03) | (5.51) | 1.05 | 61.65 | 110.63 | 156.92 | 174.35 | 112.90 | 60.44 | 61.02 |
Capex to Sales |
0.00 | — | — | — | — | — | — | — | — | — |
Columns are period end dates